- $3.96bn
- $6.23bn
- $1.38bn
- 61
- 68
- 94
- 87
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,533 | 1,003 | 2,284 | 3,838 | 1,376 |
Cost of Revenue | |||||
Gross Profit | 1,019 | 551 | 1,766 | 3,171 | 833 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,733 | 1,629 | 1,178 | 1,267 | 1,071 |
Operating Profit | -201 | -626 | 1,105 | 2,571 | 305 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 59.7 | -603 | -637 | -212 | 2,223 |
Provision for Income Taxes | |||||
Net Income After Taxes | 31.9 | -429 | -499 | -142 | 1,721 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -80.7 | -484 | -499 | -142 | 1,721 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -80.7 | -484 | -499 | -142 | 1,726 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.752 | -0.785 | -2.33 | -0.692 | 8.46 |